Board of Directors
Steven James (Chairman)
CEO, Pionyr Immunotherapeutics, Inc.
Steven James serves as Chairman of Antiva Biosciences’ Board of Directors. Mr. James is a veteran biotech CEO, having led KAI Pharmaceuticals to its acquisition by Amgen and most recently, Labrys Biologics, which was acquired by Teva. Currently, he sits on the boards of Chrono Therapeutics, and Allakos, Inc., and is the CEO of Pionyr Immunotherapeutics, Inc.
Michael Cannon has over forty years of experience in the pharmaceutical industry. He worked for twenty years at SICOR, a Swiss-Italian API manufacturing company, in a variety of positions in manufacturing, quality and regulatory affair before moving to business development. He was a member of the team that conducted the merger of SICOR with Gensia of San Diego in 1997. He served as a member of SICOR’s board and president of the biotech division until the company was sold to Teva in 2004. Mr. Cannon is now a board member of Waterstone, a Chinese pharmaceutical company, as well as Osel and BioSentinel, both in the US.
Wende S. Hutton
General Partner, Canaan
Wende Hutton identifies, builds and invests in companies that can change the practice of medicine by bringing novel drugs, technologies and devices to market. She joined Canaan in 2004 and throughout her career she has partnered with founders to deliver more than a dozen of those innovations to patients. Her track record includes seven IPOs and six acquisitions. Wende currently sits on the boards of Antiva Biosciences, Chrono Therapeutics, Glooko, Hyalex Orthopaedics, and OncoResponse. Her prior investments include BiPar Sciences (acquired by Sanofi-Aventis), Chimerix (CMRX), Dermira (DERM), Labrys Biologics (acquired by Teva Pharmaceutical) and Transcend Medical (acquired by Alcon/Novartis). Wende was recognized among Fierce Biotech’s 2014 “Fierce 15” women in biotech.
David Kabakoff, PhD
Executive Partner, Sofinnova Ventures
David Kabakoff has been an Executive Partner with Sofinnova since 2007 and a Partner in HealthQuest Capital since 2013. Prior to entering venture capital, David had more than 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, diagnostics, and drug delivery fields. David currently serves as Chairman of NextCure, Chairman of Lineagen, as a Director of Dauntless Pharmaceuticals, Principia Biosciences, BioClin Therapeutics, Castle Biosciences and BioTheranostics. Formerly he served as Chairman of Trius Therapeutics (acquired by Cubist), Chairman of Amplimmune (acquired by AstraZeneca), as a Director of lnterMune, Inc. (acquired by Roche), and Director of Allylix, Inc. (acquired by Evolva). Dr. Kabakoff also served as a Board Observer at Intellikine (acquired by Takeda).
President & CEO, Brace Pharma Capital
Vinzenz Ploerer has 30+ years of extensive leadership experience in operations, acquisitions and business development and currently serves on several life science company boards. Prior to launching Brace, he worked at EMS S/A as Senior Vice President of Strategy and Operations. He has held various leadership positions at Novartis/Sandoz including country head of Brazil, Argentina and Head of BDL Sandoz, building the company through acquisitions. Mr. Ploerer holds an M.B.A. in Strategy from Leopold-Franzens Universität Innsbruck, participated in Novartis Leadership Program at Harvard Business School, and attended the Advance Management Program at Insead Fontainbleau.
Benjamin Rovinski, PhD
Managing Director, Lumira Ventures
Benjamin Rovinski has 30 years of investment, operational, managerial and research experience in the healthcare sector, including 13 years at Sanofi Pasteur, where he led global R&D programs in areas such as HIV/AIDS and therapeutic cancer vaccines. He received a PhD in biochemistry from McGill University in Montréal and did post-doctoral studies in molecular oncology and retrovirology at the Ontario Cancer Institute in Toronto. Beni joined Lumira Ventures in 2001 and his current and past board roles include Aurinia Pharmaceuticals (NASDAQ: AUPH); G1 Therapeutics (NASDAQ: GTHX); KAI Pharmaceuticals (acquired by Amgen); Morphotek (acquired by Eisai); Health Hero Network (acquired by Bosch); Avalon Pharmaceuticals (NASDAQ: AVRX; acquired by Clinical Data, Inc.); and SGX Pharmaceuticals (NASDAQ: SGXP; acquired by Eli Lilly).
QingQing (Michael) Yi
Partner, Hillhouse Capital Management
Mr. Qingqing (Michael) Yi is currently a Partner at Hillhouse Capital Group and has worked with Hillhouse since its inception in 2005. Mr. Yi leads Hillhouse‘s healthcare investments and is currently a director of BeiGene, Ltd. Prior to joining Hillhouse, Mr. Yi was an Equity Research Analyst at China International Capital Corporation. He received a B.S in Engineering from Shanghai Maritime University, as well as an M.B.A. from University of Southern California.
President & CEO, Antiva Biosciences
Gail Maderis brings over 20 years of leadership in biopharmaceutical companies to the Antiva team. From 2009 to 2015, Gail led BayBio, the industry organization representing and supporting Northern California’s life science community. From 2003 to 2009, Gail served as President and CEO of Five Prime Therapeutics, Inc., a protein discovery and development company. At FivePrime, she successfully funded the company’s rapid growth through substantial private equity financings and corporate partnerships and took the company’s first novel cancer therapeutic from discovery into clinical trials. Prior to FivePrime, Gail held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Gail also practiced management and strategy consulting with Bain & Co. She currently serves on the board of NovaBay Pharmaceuticals (NBY) and is a Trustee of the University of California Berkeley Foundation. She received a BS in business from UC Berkeley and an MBA from Harvard Business School.